Logan Greg J, Dabbs David J, Lucas Peter C, Jankowitz Rachel C, Brown Daniel D, Clark Beth Z, Oesterreich Steffi, McAuliffe Priscilla F
Womens Cancer Research Center, University of Pittsburgh Cancer Institute, Pittsburgh, PA, 15213, USA.
Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA, 15213, USA.
Breast Cancer Res. 2015 Jun 4;17:76. doi: 10.1186/s13058-015-0580-5.
Lobular carcinoma in situ (LCIS) is considered to be a risk factor for the development of invasive breast carcinoma, but it may also be a non-obligate precursor to invasive lobular carcinoma (ILC). Many LCIS lesions do not progress to ILC, and the molecular changes that are necessary for progression from LCIS to ILC are poorly understood. Disruption in the E-cadherin complex is the hallmark of lobular lesions, but other signaling molecules, such as PIK3CA and c-src, are consistently altered in LCIS. This review focuses on the molecular drivers of lobular carcinoma, a more complete understanding of which may give perspective on which LCIS lesions progress, and which will not, thus having immense clinical implications.
小叶原位癌(LCIS)被认为是浸润性乳腺癌发生的一个危险因素,但它也可能是浸润性小叶癌(ILC)的非必需前体。许多LCIS病变不会进展为ILC,而且从LCIS进展到ILC所需的分子变化尚不清楚。E-钙黏蛋白复合物的破坏是小叶病变的标志,但其他信号分子,如PIK3CA和c-src,在LCIS中也经常发生改变。本综述聚焦于小叶癌的分子驱动因素,对其更全面的理解可能有助于了解哪些LCIS病变会进展,哪些不会,从而具有巨大的临床意义。